Association of paraoxonase 1 gene polymorphism and enzyme activity with carotid plaque in rheumatoid arthritis

Arthritis and Rheumatism

Volumn 65, Issue 11, 2013, Pages 2765-2772

  Charles Schoeman, Christina ^a   Lee, Yuen Yin ^a   Shahbazian, Ani ^a   Gorn, Alan H ^a   Fitzgerald, John ^a   Ranganath, Veena K ^a   Taylor, Mihaela ^a   Ragavendra, Nagesh ^a   McMahon, Maureen ^a   Elashoff, David ^a   Reddy, Srinivasa T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ARYLDIALKYLPHOSPHATASE 1; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; GENOMIC DNA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYCHLOROQUINE; LEFLUNOMIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARAOXON; PREDNISONE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CONTROLLED STUDY; DIET RESTRICTION; DNA POLYMORPHISM; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME SUBSTRATE; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT;

ADULT; AGED; ARTHRITIS, RHEUMATOID; ARYLDIALKYLPHOSPHATASE; CAROTID STENOSIS; ENZYME ACTIVATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 84886772261     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.38118     Document Type: Article

References (30)

1. Fischer LM, Schlienger RG, Matter C, Jick H, Meier CR,. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol 2004; 93: 198-200.
2. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303-7.
3. Del Rincon I, Williams K, Stern MP, Freeman GL, Escalante A,. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44: 2737-45.
4. Charles-Schoeman C, Watanabe J, Lee YY, Furst DE, Amjadi S, Elashoff D, et al. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum 2009; 60: 2870-9.
5. Charles-Schoeman C, Lee YY, Grijalva V, Amjadi S, FitzGerald J, Ranganath VK, et al. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis 2012; 71: 1157-62.
6. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 2000; 41: 1495-508.
7. Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, Jin L, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 2000; 41: 1481-94.
8. Navab M, Hama-Levy S, Van Lenten BJ, Fonarow GC, Cardinez CJ, Castellani LW, et al. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio [published erratum appears in J Clin Invest 1997;99:3043]. J Clin Invest 1997; 99: 2005-19.
9. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, et al. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 1995; 95: 774-82.
10. Mackness MI, Arrol S, Durrington PN,. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286: 152-4.
11. Durrington PN, Mackness B, Mackness MI,. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 473-80.
12. Costa LG, Cole TB, Jarvik GP, Furlong CE,. Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 2003; 54: 371-92.
13. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008; 299: 1265-76.
14. Costa LG, Vitalone A, Cole TB, Furlong CE,. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 2005; 69: 541-50.
15. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
16. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
17. Fries JF, Spitz P, Kraines RG, Holman HR,. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
18. Bild DE, Detrano R, Peterson D, Guerci A, Liu K, Shahar E, et al. Ethnic differences in coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 2005; 111: 1313-20.
19. Charles-Schoeman C, Khanna D, Furst DE, McMahon M, Reddy ST, Fogelman AM, et al. Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J Rheumatol 2007; 34: 1459-64.
20. Rader DJ,. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 2006; 116: 3090-100.
21. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al, for the ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-22.
22. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al, for the dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367: 2089-99.
23. Aubry MC, Maradit-Kremers H, Reinalda MS, Crowson CS, Edwards WD, Gabriel SE,. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol 2007; 34: 937-42.
24. Isik A, Koca SS, Ustundag B, Celik H, Yildirim A,. Paraoxonase and arylesterase levels in rheumatoid arthritis. Clin Rheumatol 2007; 26: 342-8.
25. Tanimoto N, Kumon Y, Suehiro T, Ohkubo S, Ikeda Y, Nishiya K, et al. Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci 2003; 72: 2877-85.
26. Popa C, van Tits LJ, Barrera P, Lemmers HL, van den Hoogen FH, van Riel PL, et al. Anti-inflammatory therapy with tumour necrosis factor α inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann Rheum Dis 2009; 68: 868-72.
27. Elfasakhany F, Mona M, Hussein M, Beyari M, Abou-Elnoeman S,. Paraoxonase 1 (PON1) Glu 192 Arg gene polymorphism and serum paraoxonase activity in rheumatoid arthritis among Egyptians. Tanta Med Sc J 2010; 5: 103-11.
28. Evans MR, Escalante A, Battafarano DF, Freeman GL, O'Leary DH, del Rincon I,. Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis. Arthritis Rheum 2011; 63: 1211-20.
29. Kerekes G, Szekanecz Z, Der H, Sandor Z, Lakos G, Muszbek L, et al. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J Rheumatol 2008; 35: 398-406.
30. Watanabe J, Charles-Schoeman C, Miao Y, Elashoff D, Lee YY, Katselis G, et al. Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum 2012; 64: 1828-37.